Videos

At the 2023 World Congress on Gastrointestinal Cancers, Bruno Sangro, MD, PhD, discusses 4-year overall survival results from the phase 3 HIMALYA study.

At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, Amer Zeidan, MBBS, speaks on recent developments in risk stratification and treatment management among patients with high-risk and low-risk myelodysplastic syndromes.

At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Daniel DeAngelo, MD, PhD, shares insights into recent treatment developments and diagnostic criteria for patients with indolent and systemic mastocytosis.

At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, John Allan, MD, analyzes the role of BTK inhibitors and combination therapies in the frontline treatment of patients with chronic lymphocytic leukemia.

At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Carla Casulo, MD, summarizes the available treatment options for relapsed/refractory follicular lymphoma and options for managing various treatment-related toxicities.

At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, Elizabeth Brem, MD, provides insights into treatment approaches used for cases of patients with Hodgkin lymphoma.

Holly Hill, PhD, shares findings from a study on the value and clinical utility of integrative prognostic machine learning models as a tool for determining accurate predictions of outcomes among patients with MCL.

At the 2023 World Congress on Gastrointestinal Cancers, Muhammad Danyal Ahsan discusses results from a study that utilized the GENIE database to determine the potential utility of widespread functional HRD status assessment in colorectal...

At the 2023 World Congress on Gastrointestinal Cancers, Giovanni Randon, MD, presented results from a study relating clinicopathological features and immunotherapy benefit among patients with dMMR/MSI-high metastatic or unresectable gastric...

Susan M. O'Brien, MD, discusses the possible applications of pirtobrutinib, a noncovalent BTK inhibitor, for the treatment of patients with CLL.